Drugs / EMRUSOLMIN
EMRUSOLMIN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05532358 | Sep 2022 → Jan 2023 | — | MODAG GmbH | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04685265 Comparator | Dec 2020 → Nov 2022 | Parkinson disease | MODAG GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04208152 Comparator | Dec 2019 → Aug 2020 | — | MODAG GmbH | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy tevapharm.com ↗ |
| 2025-09-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy tevapharm.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMRUSOLMIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4748063 ↗ |
| Known as | anle138b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04685265 ↗ |
| Known as | Emrusolmina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4748063 ↗ |
| Known as | Emrusolmine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4748063 ↗ |
| Known as | TEV-56286 | “Drug: anle138b (TEV-56286)” NCT05532358 ↗ |
| Modality | Small molecule | “an orally bioavailable small molecule compound” PMID 35500536 ↗ Apr 2022 |
| Route | Oral | “orally administered anle138b” NCT04208152 ↗ |